Edison, NJ -- (SBWIRE) -- 09/10/2020 -- Japan Pharma Outlook 2020: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Japan Pharma Outlook 2020: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives Market.
You can get free access to samples from the report here: https://www.htfmarketreport.com/sample-report/2827034-japan-pharma-outlook-2020
Japan Pharma Outlook 2020: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives Market Overview:
The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strategies to adopt with new regulations. For the innovators – testing Authorized Generics (AGs) phenomenon for protecting their long-listed sales against generic could be one of new choice in Japan. The format and regulations for AG's are still not clear in Japan, however with the largest Japanese product Blopress AG's launched recently and generic companies in queue to compete with their generic versions will make the things lucid for the fate of AG's in Japan.
Japan Pharma Outlook 2020: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives Market: Demand Analysis & Opportunity Outlook 2025
Japan Pharma Outlook 2020: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives research study is to define market sizes of various segments & countries by past years and to forecast the values by next 5 years. The report is assembled to comprise each qualitative and quantitative elements of the industry facts including: market share, market size (value and volume 2014-19, and forecast to 2025) which admire each countries concerned in the competitive examination. Further, the study additionally caters the in-depth statistics about the crucial elements which includes drivers & restraining factors that defines future growth outlook of the market.
Important years considered in the study are:
Historical year – 2014-2019 ; Base year – 2019; Forecast period** – 2020 to 2025 [** unless otherwise stated]
Enquire for customization in Report @ https://www.htfmarketreport.com/enquiry-before-buy/2827034-japan-pharma-outlook-2020
Japan Pharma Outlook 2020:
For most of the generic companies focusing on reducing manufacturing costs, and for many of them to venture in biosimilars space as a new growth avenue would be focus. The trends suggest that Japanese companies may need to set up or alliance with companies overseas for manufacturing. In this note of Outlook-15, we look deeper into these trends to anticipate likely near term changes of Japanese pharma industry.
In innovation space, after Oncology, regenerative medicine and Orphan disease are the areas where Japanese innovator companies are focusing its R & D efforts. While from late stage pipeline/new launch, Edoxaban, Lenvatinib, Entyvio, Brintellix, and Ixazomib are the few important NCEs, uptake of which will decide Japanese Innovator growth in Global market. In this report- We analyzed pipeline, strategies and key growth drivers of 13 major Japanese biopharma companies (Pure play innovators/ Innovators+ Generics/Pure play generics) and detailed our view on these growth drivers along with their interest for inlicensing external innovation from the globe for increasing R&D productivity.
Buy this research report @ https://www.htfmarketreport.com/buy-now?format=1&report=2827034
Key Answers Captured in Study are
Which geography would have better demand for product/services?
What strategies of big players help them acquire share in regional market?
Countries that may see the steep rise in CAGR & year-on-year (Y-O-Y) growth?
How feasible is market for long term investment?
What opportunity the country would offer for existing and new players in the Japan Pharma Outlook 2020: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives market?
Risk side analysis involved with suppliers in specific geography?
What influencing factors driving the demand of Japan Pharma Outlook 2020: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives near future?
What is the impact analysis of various factors in the Japan Pharma Outlook 2020: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives market growth?
What are the recent trends in the regional market and how successful they are?
Read Detailed Index of full Research Study at @ https://www.htfmarketreport.com/reports/2827034-japan-pharma-outlook-2020
TOC of Japan Pharma Outlook 2020: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives market.
2015 –Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives
Company Analysis:
Astellas - Xtandi uptake in Pre-chemo PC, Isavuconazole US approval & Uptake will provide cushion to Next batch of innovation (Roxadustat, CMV vaccine, ASP8273)!
- Xtandi- Xtandi's early stage clinical data in HER2 positive, HR+ve, AR +ve Breast cancer and Data from TERRAIN/STRIVE study in early PC will drive Xtandi momentum in 2015, while PhIII data read out of ARN-509 from SPARTAN study is the key near term threat
- Isavuconazole: Our view on US approval and Uptake
- Myrbetriq: Myrbetriq uptake in OAB market – a blockbuster potential likely- EB178 (FDC/combo of Solifenacin+ Mirabegron) combination - Next Batch of Innovation
- Roxadustat- Can change the current treatment paradigm mainly in CKD-NDPatients- AKB-6548 is the key competitor
o Key advantage over current EPO
o Biosimilar EPO is not a threat
o Pipeline HIF inhibitors and clinical data comparison
- ASP-8273 (Ph 1, Irreversible mutant selective EGFR inhibitor)
- Evolocumab
Table 1: Deals done by Astellas in 2013, 2014
Table 2: Pipeline Early stage Androgen Receptor antagonist
Table 3: Competitive landscape for Antifungals
Table 4: Competitive landscapes for OAB drugs
Table 5: Pipeline HIF alpha stabilizer- AKEBIA AKB-6548 is closest competitor
Table 6: Competitive landscape- Anti PCSK9 MAB- ALIROCUMAB vs. EVOLOCUMAB
Chart: 1, 2 – Current and Future use of anti androgens in treatment of Prostate Cancer Chugai - Alectinib, ACE910 Global Success – Next Growth Driver! ………… Continued
Thanks for reading full article, contact us at sales@htfmarketreport.com to better understand detailed research methodology and approach behind this study.
About HTF Market Report
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the "Accurate Forecast" in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their "Goals & Objectives".
Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com